A detailed history of Fifth Third Bancorp transactions in Biogen Inc. stock. As of the latest transaction made, Fifth Third Bancorp holds 3,359 shares of BIIB stock, worth $583,760. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,359
Previous 3,536 5.01%
Holding current value
$583,760
Previous $819,000 20.51%
% of portfolio
0.0%
Previous 0.0%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 17, 2024

SELL
$189.07 - $236.8 $33,465 - $41,913
-177 Reduced 5.01%
3,359 $651,000
Q2 2024

Jul 22, 2024

BUY
$190.52 - $236.72 $104,976 - $130,432
551 Added 18.46%
3,536 $819,000
Q1 2024

Apr 23, 2024

SELL
$212.02 - $267.71 $28,622 - $36,140
-135 Reduced 4.33%
2,985 $643,000
Q4 2023

Jan 19, 2024

SELL
$222.59 - $267.94 $29,159 - $35,100
-131 Reduced 4.03%
3,120 $807,000
Q3 2023

Oct 31, 2023

SELL
$253.3 - $285.89 $178,323 - $201,266
-704 Reduced 17.8%
3,251 $835,000
Q2 2023

Jul 25, 2023

BUY
$275.25 - $318.06 $13,212 - $15,266
48 Added 1.23%
3,955 $1.13 Million
Q1 2023

Apr 24, 2023

BUY
$256.56 - $292.34 $139,055 - $158,448
542 Added 16.11%
3,907 $1.09 Million
Q4 2022

Jan 25, 2023

BUY
$252.44 - $306.72 $96,936 - $117,780
384 Added 12.88%
3,365 $0
Q3 2022

Oct 25, 2022

SELL
$194.69 - $268.46 $14,991 - $20,671
-77 Reduced 2.52%
2,981 $796,000
Q2 2022

Aug 04, 2022

SELL
$187.54 - $223.02 $42,008 - $49,956
-224 Reduced 6.83%
3,058 $624,000
Q1 2022

Apr 19, 2022

SELL
$193.77 - $244.14 $1.16 Million - $1.47 Million
-6,002 Reduced 64.65%
3,282 $691,000
Q4 2021

Feb 01, 2022

SELL
$223.92 - $287.77 $412,684 - $530,360
-1,843 Reduced 16.56%
9,284 $2.23 Million
Q3 2021

Oct 15, 2021

SELL
$282.99 - $369.05 $1.76 Million - $2.3 Million
-6,220 Reduced 35.86%
11,127 $3.15 Million
Q2 2021

Aug 06, 2021

SELL
$259.0 - $414.71 $1.09 Million - $1.75 Million
-4,217 Reduced 19.56%
17,347 $6.01 Million
Q1 2021

May 07, 2021

SELL
$242.95 - $284.63 $522,585 - $612,239
-2,151 Reduced 9.07%
21,564 $6.03 Million
Q4 2020

Feb 16, 2021

SELL
$236.26 - $355.63 $615,693 - $926,771
-2,606 Reduced 9.9%
23,715 $5.81 Million
Q3 2020

Nov 09, 2020

SELL
$264.77 - $305.71 $590,437 - $681,733
-2,230 Reduced 7.81%
26,321 $7.47 Million
Q2 2020

Aug 05, 2020

SELL
$258.66 - $342.55 $292,544 - $387,424
-1,131 Reduced 3.81%
28,551 $7.64 Million
Q1 2020

May 05, 2020

SELL
$268.85 - $341.04 $1.58 Million - $2.01 Million
-5,885 Reduced 16.55%
29,682 $9.39 Million
Q4 2019

Feb 14, 2020

SELL
$220.06 - $304.07 $2.1 Million - $2.9 Million
-9,544 Reduced 21.16%
35,567 $10.6 Million
Q3 2019

Nov 14, 2019

SELL
$217.44 - $243.88 $3.38 Million - $3.79 Million
-15,539 Reduced 25.62%
45,111 $10.5 Million
Q2 2019

Aug 07, 2019

SELL
$219.29 - $241.72 $581,995 - $641,524
-2,654 Reduced 4.19%
60,650 $14.2 Million
Q1 2019

May 14, 2019

SELL
$216.71 - $338.96 $2.05 Million - $3.21 Million
-9,469 Reduced 13.01%
63,304 $15 Million
Q4 2018

Feb 14, 2019

SELL
$278.5 - $352.75 $4.18 Million - $5.29 Million
-15,005 Reduced 17.09%
72,773 $21.9 Million
Q3 2018

Nov 14, 2018

BUY
$293.51 - $383.83 $2.79 Million - $3.65 Million
9,522 Added 12.17%
87,778 $31 Million
Q2 2018

Aug 14, 2018

BUY
$257.52 - $306.91 $35,537 - $42,353
138 Added 0.18%
78,256 $22.7 Million
Q1 2018

May 15, 2018

BUY
$260.13 - $367.91 $1.26 Million - $1.78 Million
4,828 Added 6.59%
78,118 $21.4 Million
Q4 2017

Feb 14, 2018

SELL
$307.64 - $344.58 $728,491 - $815,965
-2,368 Reduced 3.13%
73,290 $23.3 Million
Q3 2017

Nov 14, 2017

SELL
$281.15 - $329.69 $244,881 - $287,159
-871 Reduced 1.14%
75,658 $23.7 Million
Q2 2017

Aug 11, 2017

BUY
N/A
76,529
76,529 $20.8 Million

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $25B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Fifth Third Bancorp Portfolio

Follow Fifth Third Bancorp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fifth Third Bancorp, based on Form 13F filings with the SEC.

News

Stay updated on Fifth Third Bancorp with notifications on news.